ENXTPA:FDJU
ENXTPA:FDJUHospitality

FDJ United (ENXTPA:FDJU) Valuation Check After Sharp Share Price Slide Despite Rising Earnings

FDJ United (ENXTPA:FDJU) has quietly slipped this year, with the stock down sharply over the past 3 months and year, even as revenue and net income keep grinding higher in the background. See our latest analysis for FDJ United. That slide has come despite the company completing its rebrand to FDJ United and continuing to post steady top line and earnings growth. The year to date share price return of negative 38.09 percent has dragged longer term total shareholder returns lower and is...
ENXTPA:MLHK
ENXTPA:MLHKAerospace & Defense

H&K (ENXTPA:MLHK): Reassessing Valuation After Strong Nine-Month 2025 Earnings Momentum

H&K (ENXTPA:MLHK) just posted stronger nine month 2025 results, with sales and profits up versus last year, and that earnings momentum is what has put the stock back on investors radar. See our latest analysis for H&K. Even with this earnings beat, the share price has had a rough run, with a roughly 60% year to date share price return decline and a similarly weak one year total shareholder return. This suggests sentiment is still catching up to the improving fundamentals. If this turnaround...
ENXTPA:AI
ENXTPA:AIChemicals

Air Liquide (ENXTPA:AI): Evaluating Valuation After New Hydrogen Deal and Low-Carbon Investment in China

L'Air Liquide (ENXTPA:AI) has caught fresh attention after two linked energy transition moves: a deeper hydrogen partnership with Hyundai Motor Group, and a EUR 25 million low carbon upgrade of its Yulin, China air separation unit. See our latest analysis for L'Air Liquide. Despite the latest share price at $158.46 and a softer 1 month share price return, the stock still carries solid long term momentum, with a 5 year total shareholder return of 55.67%, suggesting investors continue to back...
ENXTPA:BIM
ENXTPA:BIMMedical Equipment

How bioMérieux’s New Equine Hormone Tests At bioMérieux (ENXTPA:BIM) Has Changed Its Investment Story

In early December 2025, bioMérieux launched two equine endocrinology immunoassays, VIDAS Equine INSULIN and VIDAS Equine ACTH, delivering rapid point-of-care hormone testing for Equine Metabolic Syndrome and Cushing’s disease via the VIDAS KUBE platform in the UK and France, with wider rollout planned. By bringing laboratory-standard, on-demand diagnostics for common equine endocrine disorders to veterinary practices, bioMérieux is extending its human clinical testing expertise into a...
ENXTPA:SOI
ENXTPA:SOISemiconductor

How Investors May Respond To Soitec (ENXTPA:SOI) Advancing 28Si FD-SOI For European Quantum Chip Supply Chains

In recent days, Soitec announced a collaboration with Quobly and STMicroelectronics to integrate custom 28Si FD-SOI substrates into STMicro’s 300mm fab, aiming for single-qubit gate fidelities near 99.999% and creating a fully integrated European supply chain for quantum integrated circuits. This is the first global use of FD-SOI technology with a 28Si-enriched channel, potentially positioning Soitec as a key materials partner for industrial-scale silicon-based quantum processors. We’ll now...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

Is It Too Late To Consider TotalEnergies After Strong Multi Year Share Price Gains?

Wondering if TotalEnergies is still good value after a strong multi year run, or if most of the upside is already priced in? This breakdown is designed to give you a clear, no nonsense view. The stock has slipped 2.3% over the last week but is still up 0.9% over 30 days, 3.9% year to date and 11.2% over the past year, on top of a 107.9% gain over five years. Recent headlines have focused on TotalEnergies doubling down on its integrated energy strategy, from expanding LNG projects and...
ENXTPA:BVI
ENXTPA:BVIProfessional Services

Assessing Bureau Veritas After Recent ESG Expansion and Share Price Weakness in 2025

Wondering if Bureau Veritas is quietly turning into a value opportunity, or if the recent share price drift is a warning sign? This article will walk you through what the numbers really say. The stock has slipped recently, down about 3.0% over the last week, 8.3% over the last month, and 10.6% year to date, but longer term holders are still sitting on gains of 15.4% over three years and 30.8% over five years. Recent headlines have focused on Bureau Veritas expanding its role in...
ENXTPA:SU
ENXTPA:SUElectrical

Is Schneider Electric (ENXTPA:SU) Undervalued After Its Recent Share Price Lift?

Schneider Electric (ENXTPA:SU) has quietly pushed higher, with the stock up around 2% over the past week and roughly 3% in the past 3 months, despite a slightly negative year-to-date performance. See our latest analysis for Schneider Electric. Zooming out, that recent lift in Schneider Electric’s share price to about €239 sits against a modestly negative year to date share price return, while a much stronger multi year total shareholder return hints that long term momentum is still broadly...
ENXTPA:SOP
ENXTPA:SOPIT

Sopra Steria Group (ENXTPA:SOP) Is Up 7.5% After Naming Rajesh Krishnamurthy Future CEO

Sopra Steria announced that its board has appointed Rajesh Krishnamurthy as Group Chief Executive Officer, effective February 2, 2026, bringing three decades of international technology, consulting and transformation experience across Europe, Asia and the Americas. His track record in scaling Infosys and transforming Expleo, including shifting toward digital engineering and AI-enabled services, aligns closely with Sopra Steria’s ambitions in high-value, technology-led offerings. We’ll now...
ENXTPA:CAP
ENXTPA:CAPIT

Capgemini (ENXTPA:CAP) Deepens EU Cyber Mandate: What Does This Signal About Its Security Strategy?

Earlier this month, Capgemini announced it had been selected by the European Commission’s Directorate‑General for Digital Services, alongside Airbus Protect, PwC and NVISO, to deliver multi‑million Euro cybersecurity services over four years to 71 EU institutions, bodies and agencies under the MC17 FREIA Cyber Framework Contract. This wide‑ranging mandate deepens Capgemini’s role in supporting EU cyber resilience and digital sovereignty, spanning incident response, governance, risk...
ENXTPA:STMPA
ENXTPA:STMPASemiconductor

STMicroelectronics (ENXTPA:STMPA) Valuation After €1 Billion EIB Credit Line for R&D and Chip Capacity

The latest catalyst for STMicroelectronics (ENXTPA:STMPA) is a new €1 billion credit line from the European Investment Bank, with an initial €500 million tranche earmarked for R&D and high volume chip production. See our latest analysis for STMicroelectronics. Despite this sizeable backing and a solid revenue growth profile, sentiment has been subdued, with the share price down around 7.6% year to date and the three year total shareholder return sitting at roughly negative 36%. This suggests...
ENXTPA:EL
ENXTPA:ELMedical Equipment

EssilorLuxottica (ENXTPA:EL): Reassessing Valuation After a Recent Share Price Pullback

EssilorLuxottica Société anonyme (ENXTPA:EL) has quietly pulled back over the past month, slipping around 10%, even as its one year and three year returns remain strongly positive for long term shareholders. See our latest analysis for EssilorLuxottica Société anonyme. The recent 30 day share price return of around minus 9.7% has cooled EssilorLuxottica Société anonyme’s earlier momentum, but its year to date share price gain and strong multi year total shareholder returns still point to a...
ENXTPA:OR
ENXTPA:ORPersonal Products

Does L'Oréal Still Shine At €371 After Steady 2025 Gains And DCF Fair Value Signals

Wondering if L'Oréal at around €371.95 is still a beauty worth paying up for, or if the share price has already had its glow up? This article will walk through whether the current tag looks stretched or still attractive. The stock has quietly added 0.9% over the last week, 4.3% over the past month, and is up 10.0% year to date, with a solid 9.9% gain over the last year that builds on strong multi year compounding. Those moves have come as investors continue to back premium beauty and skin...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

Is Tikehau Capital’s Enlarged Revolving Credit Facility Altering The Investment Case For Tikehau (ENXTPA:TKO)?

Tikehau Capital recently renewed and upsized its Revolving Credit Facility, lifting available capacity from €800 million to €1.15 billion and extending potential maturity from 2030 to 2032, with participation from 15 banks across Europe, North America, and Asia. This larger, oversubscribed facility and lower current drawing of €275 million versus €350 million in June 2025 highlight increased financing flexibility and broad lender confidence in the group’s balance sheet strength. We’ll now...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

MedinCell (ENXTPA:MEDCL) Is Up 12.6% After Strong H1 Results And Teva’s FDA Filing - What's Changed

In the past week, MedinCell reported stronger-than-expected H1 2026 earnings while partner Teva submitted a New Drug Application to the FDA for their jointly developed olanzapine long-acting injectable for schizophrenia, alongside progress on multiple late-stage and partnered programs. The combination of UZEDY’s performance, the FDA filing for olanzapine LAI, and new backing for pipeline assets such as the AbbVie and Gates Foundation-supported programs signals a broadening of MedinCell’s...
ENXTPA:ML
ENXTPA:MLAuto Components

Is Michelin Turning into a Value Opportunity After Recent Specialty and Premium Segment Expansion?

Investors may be wondering whether Compagnie Générale des Établissements Michelin Société en commandite par actions is quietly turning into a value opportunity, or if the market already reflects its true worth. The share price is down 0.3% over the last week, 3.4% over the past month and 13.3% year to date. However, it is still up 18.9% over three years and 22.2% over five years, which suggests a mix of recent pessimism and longer term resilience. Recent headlines have focused on Michelin's...
ENXTPA:VK
ENXTPA:VKEnergy Services

Vallourec (ENXTPA:VK) Valuation Check as New CFO Nathalie Delbreuve Prepares to Take Over

Vallourec (ENXTPA:VK) is back on investors radar after naming former Verallia finance chief Nathalie Delbreuve as its new CFO. This leadership shift could subtly reshape capital allocation and balance sheet strategy. See our latest analysis for Vallourec. The timing of Delbreuve’s arrival comes as Vallourec’s share price return has softened in recent months, even though the three and five year total shareholder returns remain strongly positive. This suggests long term investors still see a...